HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing In Brief

This article was originally published in The Rose Sheet

Executive Summary

Revance Therapeutics: Biopharmaceutical company announces launch of Relastin Eye Silk, a topical product designed to increase the elasticity of skin around eyes. Item is "the first product to clinically demonstrate the ability to restore the 'spring'" of skin by "promot[ing] the formation of functional elastin," a protein in skin that the body stops producing as one ages. In clinical studies Relastin Eye Silk, which features the patent-pending Zinc Firming Complex, was shown to "significantly decrease" fine lines and wrinkles, coarse wrinkles, and under-eye laxity, puffiness and dark circles after four weeks of use, the Mountain View, Calif. firm says. Niquette Hunt, VP of cosmetic and OTC products for Revance Therapeutics, states: "These findings give us the opportunity to provide skin-care products that actually work at the cellular level to decrease the visible signs of aging." Relastin Eye Silk retails for $69

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel